The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit.
Several epidemiological studies have suggested that increased iron stores are associated with increased atherosclerotic events. In order to test the hypothesis that decreasing the vascular level of iron slows lesion growth, we examined the effects of the iron chelator Desferal (72 mg/kg/day, 5 days/week) on atherosclerosis and lesion iron content in cholesterol-fed New Zealand White rabbits. Rabbits were fed with a 1% w/w cholesterol diet for either 8 weeks (and for the last 5 weeks injected daily with Desferal) or 12 weeks (and for the last 9 weeks injected with Desferal). Controls were injected with saline. A significant reduction in average lesion area (p = 0.038) was observed in the 12-week treated animals compared with the 12-week controls. The average lesion iron level of the 12-week treated animals (58 ppm dry wt) was also significantly lower (p = 0.030) than in 12-week control animals (95 ppm dry wt), as measured using nuclear microscopy with the combination of scanning transmission ion microscopy, Rutherford back-scattering spectroscopy, and particle-induced X-ray emission. No reduction in lesion area or iron content was observed in the 8-week treated animals compared with controls, and no change in lesion zinc concentration was observed for either group. Our data strengthen the concept that iron contributes to the early stages of the development of atherosclerosis.
Minqin
Ren
R
Centre for Ion Beam Applications, Department of Physics, National University of Singapore, Singapore 117597.
Rajendran
Reshmi
R
Pan
Ning
N
Tan
Benny Kwong-Huat
BK
Ong
Wei-Yi
WY
Watt
Frank
F
Halliwell
Barry
B
D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage*; D003676:Deferoxamine / Q000494:pharmacology*; D007501:Iron / Q000097:blood / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology*; D011817:Rabbits; D014280:Triglycerides / Q000097:blood
D002791:Cholesterol, Dietary; D007502:Iron Chelating Agents; D014280:Triglycerides; D002784:Cholesterol; D007501:Iron; D003676:Deferoxamine